CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Ocular Therapeutix, Inc.

OCUL
$2.21BMid Cap

Next catalyst

Phase 3January 2027

OTX-TKI

Neovascular Age-related Macular Degeneration

Get an email about OCUL's next catalysts

Track Ocular Therapeutix (OCUL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 3 readout, PDUFA date).See the timeline

Catalyst Timeline

3 upcoming, 1 past

Phase 3Next

OTX-TKI Phase 3 Est. Readout

January 2027~OTX-TKI825

Estimated primary completion for OTX-TKI trial (NCT06495918) in Neovascular Age-related Macular Degeneration. Topline data typically follows completion by weeks to months.

Source
Phase 3

Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 Phase 3 Est. Readout (HELIOS-3)

March 2027~Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24930

Estimated primary completion for Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 trial (NCT07235085) in Non-Proliferative Diabetic Retinopathy. Topline data typically follows completion by weeks to months.

Source
PDUFA

FDA PDUFA Date Axpaxli

June 2027~Axpaxli

For wet age-related macular degeneration (wet AMD). NDA submitted. AI-extracted from: Ocular to submit Axpaxli NDA for wet AMD in Q4

Source

How OCUL's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaBEDFORD274 employees
Drug Pipeline

Frequently asked questions

What is in Ocular Therapeutix, Inc.'s drug pipeline?→

CatalystAlert tracks 16 drug candidates in Ocular Therapeutix, Inc.'s (OCUL) pipeline across Phase 3, Phase 2. Its lead program is Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Ocular Therapeutix, Inc.'s next FDA catalyst?→

Ocular Therapeutix, Inc.'s (OCUL) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track OCUL biotech catalysts?→

Add OCUL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocular Therapeutix, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply